Alvotech and Teva have confirmed that their AVT04 proposed Stelara (ustekinumab) biosimilar has been accepted for filing by the US Food and Drug Administration, ahead of the blockbuster biologic brand’s US composition of matter patent expiring later this year.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?